Merck $MRK posted better-than-expected fiscal third quarter results. For the concluded quarter, EPS was $1.07, bettering forecast by $0.09. Revenue came at $10.54 billion, a 4.7% growth Y-o-Y, and beating estimates by $360 million. Worldwide sales for the quarter were $10.5 billion, a 5% growth, including a 1% negative impact from foreign exchange. GAAP EPS was $0.78 and third quarter Non-GAAP was $1.07. For the fiscal 2016, the drug-maker gave EPS guidance of $2.02 to $2.09. Full-year 2016 Non-GAAP EPS is expected between $3.71 and $3.78.